 |
Exact Sciences Prices Public Offering of Common Stock
Jun 18, 2013
|
12.0 KB |
|
| |
MADISON, Wis.--(BUSINESS WIRE)--
Exact Sciences Corp. (NASDAQ: EXAS) today announced the pricing of its
previously announced underwritten public offering of 5.5 million shares
of its common stock, offered at a price of $12.35 per share to the
public. The net proceeds to Exact from this offering are expected to be...
|
|
Exact Sciences Announces Proposed Public Offering of Common Stock
Jun 17, 2013
|
10.7 KB |
|
| |
MADISON, Wis.--(BUSINESS WIRE)--
Exact Sciences Corp. (NASDAQ: EXAS) today announced that it intends to
offer and sell shares of its common stock in an underwritten public
offering. The offering is subject to market and other conditions, and
there can be no assurance as to whether or when the offering may be
...
|
|
Exact Sciences Submits Final Module and Completes Cologuard Premarket Approval Application to FDA, Expands Role of COO Arora
Jun 10, 2013
|
11.8 KB |
|
| |
MADISON, Wis.--(BUSINESS WIRE)--
Exact Sciences Corp. (Nasdaq: EXAS) today announced that it has
submitted to the U.S. Food and Drug Administration the final module of
the premarket approval (PMA) application for Cologuard™, the company's
stool DNA (sDNA) colorectal cancer screening test. The final module,
...
|
|
Exact Sciences to Participate in June Investor Conferences
Jun 3, 2013
|
10.1 KB |
|
| |
MADISON, Wis.--(BUSINESS WIRE)--
Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company
will participate in three investor conferences during June.
Maneesh K. Arora, the company's chief financial and chief operating
officer, will make Exact's presentation at the Jefferies Global
...
|
|
Exact Sciences to Participate in May Investor Conferences
May 3, 2013
|
10.1 KB |
|
| |
MADISON, Wis.--(BUSINESS WIRE)--
Exact Sciences Corp. (Nasdaq: EXAS) today announced that Kevin T.
Conroy, the company's president and chief executive, will present at
three investor conferences during May.
Mr. Conroy will make Exact's presentation at Baird's Growth Stock
Conference in Ch...
|
|
Exact Sciences Reports First-Quarter 2013 Financial Results, Announces Addition to Board of Directors
May 1, 2013
|
17.9 KB |
|
| |
MADISON, Wis.--(BUSINESS WIRE)--
Exact Sciences Corp. (Nasdaq: EXAS) today announced its financial
results for the quarter ended March 31, 2013.
Exact reported total revenues of $1.0 million for the first quarter of
2013, compared to $1.0 million for the first quarter of 2012.
...
|
|
Exact Sciences to Host First-Quarter 2013 Results Webcast and Call
Apr 26, 2013
|
10.8 KB |
|
| |
MADISON, Wis.--(BUSINESS WIRE)--
Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company
will host a webcast and conference call to discuss its first-quarter
2013 financial results on May 1, 2013.
...
|
|
Top-Line Data Show Exact Sciences' Cologuard Test Demonstrates 92 Percent Sensitivity in the Detection of Colorectal Cancer
Apr 18, 2013
|
272.3 KB |
|
| |
All endpoints achieved in 10,000-patient trial of non-invasive,
convenient DNA-based screening test for colorectal cancer and
pre-cancerous polyps
MADISON, Wis.--(BUSINESS WIRE)--
Exact Sciences Corp. (Nasdaq: EXAS) today announced that preliminary
analysis shows that the company's ...
|
|
Exact Sciences Schedules Announcement and Call for Top-Line Results of DeeP-C Clinical Trial
Apr 17, 2013
|
12.3 KB |
|
| |
MADISON, Wis.--(BUSINESS WIRE)--
Exact Sciences Corp. (Nasdaq: EXAS) will announce the preliminary,
top-line results of its DeeP-C pivotal clinical trial on Thursday, April
18, 2013, prior to the market open. The company will host a webcast and
conference call to discuss the results that morning at 7:30 ET.
...
|
|
Exact Sciences to Participate in 25th Annual Roth Conference
Mar 11, 2013
|
9.7 KB |
|
| |
MADISON, Wis.--(BUSINESS WIRE)--
Exact Sciences Corp. (Nasdaq: EXAS) today announced that it will present
at the 25th Annual Roth Conference in Dana Point, Calif.
Maneesh K. Arora, Exact's chief operating and chief financial officer,
will make the company's presentation at 1 p.m. PT on Monday, Mar...
|
|
Exact Sciences Reports Fourth-Quarter 2012 Financial Results
Feb 20, 2013
|
19.2 KB |
|
| |
MADISON, Wis.--(BUSINESS WIRE)--
Exact Sciences Corp. (Nasdaq: EXAS) today announced its financial
results for the quarter and year ended Dec. 31, 2012.
Exact reported total revenues of $1.0 million for the fourth quarter of
2012 and the fourth quarter of 2011. Total revenues for the year ended
...
|
|
Exact Sciences Submits Second Module of Premarket Approval Application to FDA
Feb 18, 2013
|
9.8 KB |
|
| |
MADISON, Wis.--(BUSINESS WIRE)--
Exact Sciences Corp. (Nasdaq: EXAS) today announced that it has
submitted to the U.S. Food and Drug Administration the second module of
the premarket approval (PMA) application for its stool DNA colorectal
cancer screening test.
This module was comprised o...
|
|
Exact Sciences to Host Fourth-Quarter, Full-Year 2012 Results Webcast and Call
Feb 12, 2013
|
10.8 KB |
|
| |
MADISON, Wis.--(BUSINESS WIRE)--
Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company
will host a webcast and conference call to discuss its fourth-quarter
and full-year 2012 financial results on Feb. 20, 2013.
Fourth-Quarter 2012 Conference Call Details
...
|
|
Exact Sciences to Participate in February Investor Conferences
Feb 12, 2013
|
9.9 KB |
|
| |
MADISON, Wis.--(BUSINESS WIRE)--
Exact Sciences Corp. (Nasdaq: EXAS) today announced that it will present
at two investor conferences during February.
Kevin T. Conroy, Exact's president and chief executive, will make the
company's presentation at the Leerink Swann Global Healthcare Conference
...
|
|
Exact Sciences to Participate in J.P. Morgan Healthcare Conference
Jan 3, 2013
|
9.7 KB |
|
| |
MADISON, Wis.--(BUSINESS WIRE)--
Exact Sciences Corp. (Nasdaq: EXAS) today announced that it will present
at the J.P. Morgan Healthcare Conference in San Francisco.
Kevin T. Conroy, Exact's president and chief executive, will make the
company's presentation at 4 p.m. PT on Wednesday, Jan. 9.
...
|
|
Exact Sciences Submits First Module of Premarket Approval Application to FDA
Dec 10, 2012
|
9.7 KB |
|
| |
MADISON, Wis.--(BUSINESS WIRE)--
Exact Sciences Corp. (Nasdaq: EXAS) today announced that it has
submitted to the U.S. Food and Drug Administration the first module of
the premarket approval (PMA) application for its stool DNA colorectal
cancer screening test.
This module was comprised of...
|
|
Exact Sciences to participate in Canaccord Genuity Medical Technology & Diagnostics Forum
Nov 29, 2012
|
10.0 KB |
|
| |
MADISON, Wis.--(BUSINESS WIRE)--
Exact Sciences Corp. (Nasdaq: EXAS) today announced that it will present
at the Canaccord Genuity Medical Technology & Diagnostics Forum in New
York.
Kevin T. Conroy, Exact's president and chief executive, will make the
company's presentation at 10 a.m. ET...
|
|
Exact Sciences Completes Enrollment of DeeP-C Clinical Trial for Colorectal Cancer Screening
Nov 15, 2012
|
295.3 KB |
|
| |
More than 12,700 patients enrolled to evaluate the company's
non-invasive stool-based DNA test to detect the second leading cause of
cancer deaths
MADISON, Wis.--(BUSINESS WIRE)--
Exact
Sciences Corp. (Nasdaq: EXAS) today announced it has completed
patient enrollment in its...
|
|
Exact Sciences to Participate in November Investor Conferences
Nov 7, 2012
|
9.9 KB |
|
| |
MADISON, Wis.--(BUSINESS WIRE)--
Exact Sciences Corp. (Nasdaq: EXAS) today announced that it will present
at two investor conferences during November.
Kevin T. Conroy, Exact's president and chief executive, will make the
company's presentation at the Lazard Capital Markets 9th Annual
Heal...
|
|
Exact Sciences Reports Third-Quarter 2012 Financial Results
Oct 30, 2012
|
19.8 KB |
|
| |
MADISON, Wis.--(BUSINESS WIRE)--
Exact Sciences Corp. (Nasdaq: EXAS) today announced its financial
results for the quarter ended Sept. 30, 2012.
Exact reported total revenues of $1.0 million for the third quarter of
2012 and the third quarter of 2011. Total revenues for each of the
nine-m...
|
|
|
Delicious
Digg
Facebook
LinkedIn
Twitter
